Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ADCT

Adc Therapeutics SA

Mar 03 • 04:00PM ET

4.05

-0.13 -3.11 %

Healthcare • Biotechnology • Switzerland • NYSE

Peers: GILD PFE AMGN LLY REGN VRTX JAZZ MRNA BMY INCY

| Held by: IWM IBB IWO VTWO VFMO IWC GWX VTWG IWV RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.45	Insider Own	27.02%	Shs Outstand	112.63M	Perf Week	-7.74%
Market Cap	501.71M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	0.00%	Shs Float	90.40M	Perf Month	12.19%
Enterprise Value	724.41M	PEG	-	EPS next Q	-0.27	Inst Own	59.40%	Short Float	4.83%	Perf Quarter	-5.81%
Income	-166.94M	P/S	6.67	EPS this Y	13.27%	Inst Trans	2.89%	Short Ratio	3.78	Perf Half Y	31.92%
Sales	75.21M	P/B	-	EPS next Y	20.76%	ROA	-52.26%	Short Interest	4.36M	Perf YTD	14.73%
Book/sh	-2.11	P/C	2.14	EPS next 5Y	25.03%	ROE	-	52W High	4.80 -15.62%	Perf Year	154.72%
Cash/sh	1.89	P/FCF	-	EPS past 3/5Y	18.47% 1.38%	ROIC	-76.47%	52W Low	1.05 285.71%	Perf 3Y	28.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	27.82% 97.79%	Gross Margin	89.33%	Volatility	5.65% 6.64%	Perf 5Y	-84.07%
Dividend TTM	-	EV/Sales	9.63	EPS Y/Y TTM	39.57%	Oper. Margin	-162.94%	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.34	Sales Y/Y TTM	6.35%	Profit Margin	-221.97%	RSI (14)	50.82	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.63	EPS Q/Q	28.44%	SMA20	-1.09%	Beta	1.96	Target Price	7.80
Payout	-	Debt/Eq	-	Sales Q/Q	-11.03%	SMA50	6.18%	Rel Volume	0.82	Prev Close	4.18
Employees	265	LT Debt/Eq	-	Earnings	Mar 10 BMO	SMA200	14.11%	Avg Volume	1.15M	Price	4.05
IPO	May 15, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.42% -2.18%	Trades		Volume	942,453	Change	-3.11%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Stephens	Overweight	$6
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Today 07:15AM	ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026 (PR Newswire)
Mar-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Feb-24-26 07:15AM	ADC Therapeutics to Participate in March Investor Conferences (PR Newswire)
Feb-23-26 07:15AM	ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement (PR Newswire) +7.56%
Feb-02-26 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +8.03%
10:36AM	Loading…
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-13-26 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Jan-08-26 04:05PM	ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-26 04:05PM	ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
Dec-29-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why (Zacks)
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
Dec-18-25 01:14AM	RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development (Insider Monkey) +6.27%
Dec-17-25 09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.56%
12:00PM	Loading…
Dec-15-25 12:00PM	ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy? (Zacks)
Dec-04-25 07:40AM	ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma (TipRanks) -10.38%
Dec-03-25 07:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -14.13%
Dec-02-25 04:05PM	ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial (PR Newswire) +8.49%
Dec-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-18-25 12:00PM	ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-10-25 04:01PM	ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ... (GuruFocus.com) -5.70%
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Nov-07-25 12:51PM	Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y (Zacks)
07:20AM	ADC Therapeutics SA (ADCT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-06-25 05:45PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 06:05PM	Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -6.28%
07:15AM	ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025 (PR Newswire)
07:15AM	Loading…
Oct-27-25 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Oct-26-25 06:16AM	ADC Therapeutics (ADCT) Secures PIPE Financing, Price Target Adjusted (Insider Monkey)
Oct-24-25 08:07AM	H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement (Insider Monkey)
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
07:30AM	ADC Therapeutics Announces $60 Million Private Placement (PR Newswire)
Oct-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Sep-29-25 12:56AM	ADC Therapeutics S.A. (ADCT) Eyes Billion Dollar Opportunity with ZYNLATA Indication Expansion (Insider Monkey) +10.14%
Sep-18-25 10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +6.13%
Aug-27-25 07:15AM	ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 (PR Newswire)
Aug-13-25 03:07AM	ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... (GuruFocus.com) +5.10%
Aug-12-25 03:00PM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.70%
07:30AM	ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
Aug-11-25 07:00PM	TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:34AM	ADC Therapeutics SA (ADCT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-07-25 06:10PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 04:05PM	ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 (PR Newswire)
Aug-04-25 09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Aug-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Jul-01-25 04:05PM	ADC Therapeutics Makes Grant to New Employee Under Inducement Plan (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-16-25 07:15AM	ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire) -5.59%
Jun-12-25 06:45AM	ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 (PR Newswire)
06:30AM	ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress (PR Newswire)
Jun-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) +13.59%
May-30-25 05:44AM	AbbVies ADC win shows how pharma can break through in solid tumors (Pharma Voice) +11.55%
May-15-25 07:49AM	ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data (Clinical Trials Arena) -6.63%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-14-25 09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +37.12%
08:00AM	ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
07:45AM	ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire)
May-13-25 09:42AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings (GuruFocus.com)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:15AM	ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 (PR Newswire)
May-01-25 05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +9.77%
07:00AM	ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Apr-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-25 09:00PM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.37%
Mar-27-25 11:17AM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update (PR Newswire)
Mar-25-25 05:30PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Mar-24-25 11:08PM	ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 (SeekingAlpha)
Mar-20-25 07:15AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 (PR Newswire) -6.59%
Feb-03-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -5.95%
Jan-30-25 07:15AM	ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (PR Newswire)
Jan-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Dec-30-24 04:30PM	ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma (PR Newswire) -6.40%
Dec-11-24 07:30AM	ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -36.21%
Dec-09-24 07:30AM	ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma (PR Newswire)
Dec-06-24 07:30AM	ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial (PR Newswire) +63.02%
Dec-02-24 04:30PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -10.78%
Nov-14-24 02:02AM	BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... (GuruFocus.com) -6.03%
Nov-08-24 01:14PM	ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why (Benzinga)
Nov-07-24 08:50AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.44%
07:30AM	ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update (PR Newswire)
Nov-06-24 07:41AM	What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings (GuruFocus.com)
Nov-05-24 09:47AM	ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting (PR Newswire)
Nov-04-24 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Nov-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-31-24 07:15AM	ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire)
Oct-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
Sep-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -5.86%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:40AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADCT

Adc Therapeutics SA

Upgrade your FINVIZ experience